US5846983A
(en)
*
|
1996-02-09 |
1998-12-08 |
Mayo Foundation For Medical Education And Research |
Colonic delivery of nicotine to treat inflammatory bowel disease
|
US5889028A
(en)
*
|
1996-02-09 |
1999-03-30 |
Mayo Foundation For Medical Education And Research |
Colonic delivery of nicotine to treat inflammatory bowel disease
|
AU2340397A
(en)
*
|
1996-03-21 |
1997-10-10 |
Mayo Foundation For Medical Education And Research |
Use of nicotine to treat liver disease
|
US20020052497A1
(en)
*
|
2000-03-09 |
2002-05-02 |
Targacept, Inc. |
Compounds capable of activating cholinergic receptors
|
US6166048A
(en)
*
|
1999-04-20 |
2000-12-26 |
Targacept, Inc. |
Pharmaceutical compositions for inhibition of cytokine production and secretion
|
US6979695B2
(en)
|
1996-04-23 |
2005-12-27 |
Targacept, Inc. |
Compounds capable of activating cholinergic receptors
|
US5811442A
(en)
*
|
1997-02-21 |
1998-09-22 |
Bencherif; Merouane |
Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
|
US6531606B1
(en)
*
|
1997-02-21 |
2003-03-11 |
Targacept, Inc. |
Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
|
US6525065B1
(en)
|
1997-06-30 |
2003-02-25 |
Targacept, Inc. |
Pharmaceutical compositions and methods for effecting dopamine release
|
US7214686B2
(en)
*
|
1997-06-30 |
2007-05-08 |
Targacept, Inc. |
Pharmaceutical compositions and methods for effecting dopamine release
|
US6624173B1
(en)
|
1997-06-30 |
2003-09-23 |
Targacept, Inc. |
Pharmaceutical compositions for treating and/or preventing CNS disorders
|
US5914337A
(en)
*
|
1997-08-07 |
1999-06-22 |
Virginia Commonwealth University |
Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
|
WO1999043322A1
(en)
*
|
1998-02-24 |
1999-09-02 |
Wake Forest University |
Method for the treatment of pain, including chronic and female specific pain
|
AU2880699A
(en)
|
1998-04-02 |
1999-10-25 |
R.J. Reynolds Tobacco Company |
Pharmaceutical compositions and methods for use
|
US6395273B1
(en)
|
1998-06-10 |
2002-05-28 |
Promega Corporation |
Prevention and treatment of inflammatory bowel disease
|
US7790757B2
(en)
*
|
1998-06-16 |
2010-09-07 |
Targacept, Inc. |
Compounds capable of activating cholinergic receptors
|
US6232316B1
(en)
|
1998-06-16 |
2001-05-15 |
Targacept, Inc. |
Methods for treatment of CNS disorders
|
US20050131034A1
(en)
*
|
1998-06-16 |
2005-06-16 |
Caldwell William S. |
Compounds capable of activating cholinergic receptors
|
US6218383B1
(en)
|
1998-08-07 |
2001-04-17 |
Targacept, Inc. |
Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
|
US6262124B1
(en)
|
1998-10-22 |
2001-07-17 |
Gary Maurice Dull |
Pharmaceutical compositions and methods for use
|
US6114382A
(en)
*
|
1998-11-11 |
2000-09-05 |
Moretti; Itagiba G. |
Methods for treating inflammatory bowel disease
|
US6953855B2
(en)
*
|
1998-12-11 |
2005-10-11 |
Targacept, Inc. |
3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
|
US6432975B1
(en)
|
1998-12-11 |
2002-08-13 |
Targacept, Inc. |
Pharmaceutical compositions and methods for use
|
AU2005201609B2
(en)
*
|
1999-04-20 |
2007-10-18 |
Targacept, Inc |
Pharmaceutical compositions for inhibition of cytokine production and secretion
|
US20010031771A1
(en)
|
1999-05-24 |
2001-10-18 |
Gary Maurice Dull |
Pharmaceutical compositions and methods for use
|
AU5326100A
(en)
*
|
1999-06-07 |
2000-12-28 |
Targacept, Inc. |
Pharmaceutical compositions and methods for use
|
US6455554B1
(en)
*
|
1999-06-07 |
2002-09-24 |
Targacept, Inc. |
Oxopyridinyl pharmaceutical compositions and methods for use
|
US6890935B2
(en)
*
|
1999-11-01 |
2005-05-10 |
Targacept, Inc. |
Pharmaceutical compositions and methods for use
|
US8914114B2
(en)
|
2000-05-23 |
2014-12-16 |
The Feinstein Institute For Medical Research |
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
|
US6610713B2
(en)
*
|
2000-05-23 |
2003-08-26 |
North Shore - Long Island Jewish Research Institute |
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
|
US6689788B1
(en)
*
|
2000-08-25 |
2004-02-10 |
University Of Florida |
Method and composition for treatment of inflammatory bowel disease
|
EP1463481A4
(de)
*
|
2001-12-14 |
2008-06-25 |
Targacept Inc |
Verfahren und zusammensetzungen zur behandlung von erkrankungen des zentralen nervensystems
|
US20030118329A1
(en)
*
|
2001-12-21 |
2003-06-26 |
Pere Obrador |
Video indexing using high resolution still images
|
WO2003072135A2
(en)
*
|
2002-02-26 |
2003-09-04 |
North Shore-Long Island Jewish Research Insitute |
Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
|
NZ551552A
(en)
*
|
2002-07-05 |
2008-03-28 |
Targacept Inc |
N-Aryl diazaspirocyclic compounds capable of affecting nicotinic cholinergic receptors and methods of preparation and use thereof
|
IL152127A0
(en)
*
|
2002-10-06 |
2003-05-29 |
Bio Balance Corp |
Probiotic compositions for the treatment of inflammatory bowel disease
|
US7098331B2
(en)
*
|
2003-03-05 |
2006-08-29 |
Targacept, Inc. |
Arylvinylazacycloalkane compounds and methods of preparation and use thereof
|
CA2539811A1
(en)
*
|
2003-10-15 |
2005-04-28 |
Targacept, Inc. |
Azabicycyclic compounds for relieving pain and treating central nervous system disorders
|
CA2553775A1
(en)
*
|
2004-01-20 |
2005-08-11 |
Richard F. Harty |
Compositions and methods of treatment for inflammatory diseases
|
JP2007530586A
(ja)
*
|
2004-03-25 |
2007-11-01 |
ザ ファインスタイン インスティテュート フォー メディカル リサーチ |
神経性止血法
|
US10912712B2
(en)
|
2004-03-25 |
2021-02-09 |
The Feinstein Institutes For Medical Research |
Treatment of bleeding by non-invasive stimulation
|
DE602004023237D1
(de)
*
|
2004-04-02 |
2009-10-29 |
Arterial Remodelling Technolog |
Stentanordnung auf polymerbasis
|
EP1802601A1
(de)
*
|
2004-09-20 |
2007-07-04 |
Targacept, Inc. |
Azaspiroalken- und azaspiroalkanverbindungen mit wirkung auf nikotinische acetylcholinrezeptoren
|
UA88792C2
(ru)
|
2004-11-10 |
2009-11-25 |
Таргасепт, Інк. |
Гидроксибензоатные соли метаникотиновых соединений
|
US7459469B2
(en)
|
2004-11-10 |
2008-12-02 |
Targacept, Inc. |
Hydroxybenzoate salts of metanicotine compounds
|
US11207518B2
(en)
|
2004-12-27 |
2021-12-28 |
The Feinstein Institutes For Medical Research |
Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
|
CN101124012B
(zh)
|
2004-12-27 |
2012-09-05 |
范因斯坦医学研究院 |
通过电刺激迷走神经治疗炎症性疾病的装置
|
CN101248073A
(zh)
*
|
2005-08-22 |
2008-08-20 |
塔加西普特公司 |
杂芳基-取代的二氮杂三环烷类、其制备方法及其应用
|
TWI389889B
(zh)
*
|
2006-05-09 |
2013-03-21 |
Targacept Inc |
(2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型
|
US8017785B2
(en)
*
|
2006-05-09 |
2011-09-13 |
Astrazeneca Ab |
Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
|
CL2007002684A1
(es)
*
|
2006-09-15 |
2008-06-27 |
Astrazeneca Ab Targacept Inc |
Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.
|
TWI454262B
(zh)
|
2006-11-02 |
2014-10-01 |
Targacept Inc |
菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
|
WO2008091588A1
(en)
|
2007-01-22 |
2008-07-31 |
Targacept, Inc. |
Intranasal, buccal, and sublingual administration of metanicotine analogs
|
US8571662B2
(en)
|
2007-01-29 |
2013-10-29 |
Simon Fraser University |
Transvascular nerve stimulation apparatus and methods
|
US7923014B2
(en)
*
|
2007-02-12 |
2011-04-12 |
The Board Of Regents Of The University Of Texas System |
Expression and purification of HIP/PAP and uses therefor
|
CA2680477A1
(en)
*
|
2007-03-13 |
2008-09-18 |
The Feinstein Institute For Medical Research |
Treatment of inflammation by non-invasive stimulation
|
TW200845977A
(en)
*
|
2007-03-30 |
2008-12-01 |
Targacept Inc |
Sub-type selective azabicycloalkane derivatives
|
EP2182932A2
(de)
*
|
2007-07-31 |
2010-05-12 |
Targacept Inc. |
Transdermale verabreichung von (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amin
|
SA08290475B1
(ar)
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
US8391970B2
(en)
|
2007-08-27 |
2013-03-05 |
The Feinstein Institute For Medical Research |
Devices and methods for inhibiting granulocyte activation by neural stimulation
|
KR101565469B1
(ko)
*
|
2007-10-01 |
2015-11-03 |
코멘티스, 인코포레이티드 |
알츠하이머병의 치료를 위한 알파 7 니코틴 아세틸콜린 수용체 리간드로서 퀴누클리딘-4-일메틸 1h-인돌-3-카르복실레이트 유도체
|
WO2009091561A1
(en)
*
|
2008-01-15 |
2009-07-23 |
Targacept, Inc. |
Preparation and enantiomeric separation of 7-(3-pyridinyl)-1,7-diazaspiro[4.4] nonane and novel salt forms of the racemate and enantiomers
|
CA2716863A1
(en)
*
|
2008-03-05 |
2009-09-11 |
Targacept, Inc. |
Sub-type selective amides of diazabicycloalkanes
|
US9662490B2
(en)
|
2008-03-31 |
2017-05-30 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
|
WO2009146030A1
(en)
*
|
2008-03-31 |
2009-12-03 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation of t-cell activity
|
CN102215909B
(zh)
*
|
2008-11-18 |
2014-09-10 |
赛博恩特医疗器械公司 |
优化用于消炎刺激的电极放置的装置和方法
|
TW201024283A
(en)
|
2008-12-01 |
2010-07-01 |
Targacept Inc |
Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
|
EP3279195B1
(de)
|
2008-12-01 |
2020-07-01 |
Oyster Point Pharma, Inc. |
Synthese und neuartige salzformen von (r)-5-((e)-2-pyrrolidin-3-ylvinyl)pyrimidin
|
US9145396B2
(en)
|
2008-12-01 |
2015-09-29 |
Targacept, Inc. |
Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
|
WO2010080757A2
(en)
|
2009-01-07 |
2010-07-15 |
Astrazeneca Ab |
Combinations with an alpha-4beta-2 nicotinic agonist
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
US8788034B2
(en)
|
2011-05-09 |
2014-07-22 |
Setpoint Medical Corporation |
Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
US9211410B2
(en)
|
2009-05-01 |
2015-12-15 |
Setpoint Medical Corporation |
Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
US8996116B2
(en)
|
2009-10-30 |
2015-03-31 |
Setpoint Medical Corporation |
Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
|
WO2010144578A2
(en)
|
2009-06-09 |
2010-12-16 |
Setpoint Medical Corporation |
Nerve cuff with pocket for leadless stimulator
|
US9833621B2
(en)
|
2011-09-23 |
2017-12-05 |
Setpoint Medical Corporation |
Modulation of sirtuins by vagus nerve stimulation
|
WO2014169145A1
(en)
|
2013-04-10 |
2014-10-16 |
Setpoint Medical Corporation |
Closed-loop vagus nerve stimulation
|
CN102648202A
(zh)
|
2009-12-07 |
2012-08-22 |
塔加西普特公司 |
作为神经元烟碱乙酰胆碱受体配体的3,6-二氮杂双环[3.1.1]庚烷
|
WO2011079309A2
(en)
|
2009-12-23 |
2011-06-30 |
Setpoint Medical Corporation |
Neural stimulation devices and systems for treatment of chronic inflammation
|
US20110268809A1
(en)
|
2010-04-28 |
2011-11-03 |
Paul Andrew Brinkley |
Nicotine-Containing Pharmaceutical Compositions
|
US20110274628A1
(en)
|
2010-05-07 |
2011-11-10 |
Borschke August J |
Nicotine-containing pharmaceutical compositions
|
CN103180277A
(zh)
|
2010-05-20 |
2013-06-26 |
塔格塞普特股份有限公司 |
制备芳基取代的烯属胺的新方法
|
MX337106B
(es)
|
2010-05-27 |
2016-02-12 |
Targacept Inc |
Antagonistas no competitivos de receptores nicotinicos.
|
WO2012125518A1
(en)
|
2011-03-14 |
2012-09-20 |
Targacept, Inc. |
Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
|
WO2012129262A1
(en)
|
2011-03-23 |
2012-09-27 |
Targacept, Inc. |
Treatment of attention deficit/hyperactivity disease
|
TW201311698A
(zh)
|
2011-08-22 |
2013-03-16 |
Targacept Inc |
作為神經元菸鹼乙醯膽鹼受體配位體之1,4-二氮雜雙環[3.2.2]壬烷
|
US20130078307A1
(en)
|
2011-09-22 |
2013-03-28 |
Niconovum Usa, Inc. |
Nicotine-containing pharmaceutical composition
|
US9907748B2
(en)
|
2011-10-21 |
2018-03-06 |
Niconovum Usa, Inc. |
Excipients for nicotine-containing therapeutic compositions
|
US9763928B2
(en)
|
2012-02-10 |
2017-09-19 |
Niconovum Usa, Inc. |
Multi-layer nicotine-containing pharmaceutical composition
|
WO2013131187A1
(en)
|
2012-03-05 |
2013-09-12 |
Simon Fraser University |
Transvascular nerve stimulation apparatus and methods
|
US9572983B2
(en)
|
2012-03-26 |
2017-02-21 |
Setpoint Medical Corporation |
Devices and methods for modulation of bone erosion
|
CN104684614B
(zh)
|
2012-06-21 |
2017-10-17 |
西蒙·弗雷泽大学 |
经血管的膈膜起搏系统及使用方法
|
US20140255452A1
(en)
|
2013-03-11 |
2014-09-11 |
Niconovum Usa, Inc. |
Method and apparatus for differentiating oral pouch products
|
JP6456382B2
(ja)
|
2013-11-22 |
2019-01-23 |
ラングペーサー メディカル インコーポレイテッドLungpacer Medical Inc. |
カテーテル
|
CA2935454A1
(en)
|
2014-01-21 |
2015-07-30 |
Simon Fraser University |
Systems and related methods for optimization of multi-electrode nerve pacing
|
WO2016007630A1
(en)
|
2014-07-11 |
2016-01-14 |
Alpharmagen, Llc |
Quinuclidine compounds for modulating alpha7 -nicotinic acetylcholine receptor activity
|
US11311725B2
(en)
|
2014-10-24 |
2022-04-26 |
Setpoint Medical Corporation |
Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
|
US11406833B2
(en)
|
2015-02-03 |
2022-08-09 |
Setpoint Medical Corporation |
Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
|
US9724340B2
(en)
|
2015-07-31 |
2017-08-08 |
Attenua, Inc. |
Antitussive compositions and methods
|
US20170165252A1
(en)
|
2015-12-10 |
2017-06-15 |
Niconovum Usa Inc. |
Protein-enriched therapeutic composition
|
US10596367B2
(en)
|
2016-01-13 |
2020-03-24 |
Setpoint Medical Corporation |
Systems and methods for establishing a nerve block
|
EP3405107B1
(de)
|
2016-01-20 |
2023-04-12 |
Setpoint Medical Corporation |
Steuerung der vagalstimulierung
|
US11471681B2
(en)
|
2016-01-20 |
2022-10-18 |
Setpoint Medical Corporation |
Batteryless implantable microstimulators
|
EP3405255A4
(de)
|
2016-01-20 |
2019-10-16 |
Setpoint Medical Corporation |
Implantierbare mikrostimulatoren und induktive ladesysteme
|
US10583304B2
(en)
|
2016-01-25 |
2020-03-10 |
Setpoint Medical Corporation |
Implantable neurostimulator having power control and thermal regulation and methods of use
|
US10293164B2
(en)
|
2017-05-26 |
2019-05-21 |
Lungpacer Medical Inc. |
Apparatus and methods for assisted breathing by transvascular nerve stimulation
|
EP3645107B1
(de)
|
2017-06-30 |
2022-08-31 |
Lungpacer Medical Inc. |
Systeme zur prävention, moderation und/oder behandlung von kognitiven verletzungen
|
US10195429B1
(en)
|
2017-08-02 |
2019-02-05 |
Lungpacer Medical Inc. |
Systems and methods for intravascular catheter positioning and/or nerve stimulation
|
US10940308B2
(en)
|
2017-08-04 |
2021-03-09 |
Lungpacer Medical Inc. |
Systems and methods for trans-esophageal sympathetic ganglion recruitment
|
EP3668402A4
(de)
|
2017-08-14 |
2021-05-19 |
Setpoint Medical Corporation |
Vagusnervstimulationsvorscreening-test
|
WO2019239356A1
(en)
|
2018-06-15 |
2019-12-19 |
R. J. Reynolds Tobacco Company |
Purification of nicotine
|
US11260229B2
(en)
|
2018-09-25 |
2022-03-01 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
|
WO2020097331A1
(en)
|
2018-11-08 |
2020-05-14 |
Lungpacer Medical Inc. |
Stimulation systems and related user interfaces
|
EP3968932A4
(de)
|
2019-05-16 |
2023-01-18 |
Lungpacer Medical Inc. |
Systeme und verfahren zur erfassung und stimulation
|
US11771900B2
(en)
|
2019-06-12 |
2023-10-03 |
Lungpacer Medical Inc. |
Circuitry for medical stimulation systems
|
WO2021236977A1
(en)
|
2020-05-21 |
2021-11-25 |
The Feinstein Institutes For Medical Research |
Systems and methods for vagus nerve stimulation
|